Arbutus Biopharma (ABUS) Current Deferred Revenue (2010 - 2025)

Arbutus Biopharma (ABUS) has reported Current Deferred Revenue for 13 consecutive years, with $6.8 million the latest figure, recorded in Q1 2025.

• Quarterly Current Deferred Revenue fell 41.47% year-over-year to $6.8 million in Q1 2025, while the trailing twelve-month figure through Mar 2025 was $6.8 million (down 41.47% YoY) and the FY2024 annual result came in at $7.6 million, down 35.79% from the prior year.
• Current Deferred Revenue fell to $6.8 million in Q1 2025 per ABUS's latest filing, from $7.6 million in the prior quarter.
• Over the last five years, Current Deferred Revenue for ABUS reached as high as $23.3 million in Q1 2022 and fell as low as $6.8 million in Q1 2025.
• A 4-year average of $13.4 million and a median of $12.1 million in 2023 frame the typical range for Current Deferred Revenue.
• Annual changes were most pronounced in 2023 — Current Deferred Revenue dropped 9.7% — and 2025, when it plunged 41.47%.
• Year by year, Current Deferred Revenue stood at $16.5 million in 2022, then decreased by 28.35% to $11.8 million in 2023, then tumbled by 35.79% to $7.6 million in 2024, then retreated by 10.73% to $6.8 million in 2025.
• According to Business Quant data, Current Deferred Revenue over the past three periods registered $6.8 million, $7.6 million, and $10.9 million for Q1 2025, Q4 2024, and Q3 2024 respectively.